Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Creative Funding Options For China; Investors Battle Perception of Home Court Advantage

This article was originally published in PharmAsia News

Executive Summary

The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

You may also be interested in...



Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy

Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.

Related Content

Latest News
UsernamePublicRestriction

Register

SC078314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel